Arcutis Biotherapeutics Receives FDA Approval for New Seborrheic Dermatitis Treatment\n\nArcutis Biotherapeutics (NASDAQ:ARQT) has made a breakthrough in the treatment of seborrheic dermatitis with the FDA’s approval of its drug ZORYVE. This marks the first drug approved for this condition with a new mechanism of action in over two decades. Seborrheic dermatitis is a common skin condition that affects over 10 million people in the U.S. And causes scaly patches, inflamed skin, and stubborn dandruff.\n\nZORYVE is a once-daily, steroid-free foam that has shown to be highly effective, safe, and well-tolerated in clinical trials. It can be used on all affected areas of the body, including hair-bearing areas, with no limitations on duration of use. This provides a new treatment option for patients nine years of age and older, who previously had limited options for managing their condition.\n\nThe FDA’s approval of ZORYVE is a significant milestone for Arcutis Biotherapeutics. The company’s Chief Commercial Officer, Todd Edwards, has stated that two of the top three U.S. Pharmacy benefit managers are projected to cover the product. This not only highlights the company’s strong fundamentals, but also makes it an attractive choice for those seeking treatment for seborrheic dermatitis.\n\nIn a statement released on Friday, Arcutis Biotherapeutics announced that ZORYVE is expected to be available for commercial use by the end of January. The drug has shown a success rate of 79.5% on a 5-point assessment scale in a late-stage trial, compared to a success rate of 58% for a placebo. This demonstrates the effectiveness of ZORYVE in treating seborrheic dermatitis.\n\nIn a Arcutis Biotherapeutics has received FDA approval for its drug ZORYVE, providing a new treatment option for seborrheic dermatitis. Its once-daily, steroid-free foam has shown to be highly effective, safe, and well-tolerated in clinical trials.